Evidence map›Paper›PMID 35931073›Full record

ArticleCell host & microbe2022

Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.

Chiara Pastorio, Fabian Zech, Sabrina Noettger, Christoph Jung, Timo Jacob, Theo Sanderson, Konstantin M J Sparrer, Frank Kirchhoff

Open access · hybridAbstract read
In one paragraph

Article in Cell host & microbe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Chiara PastorioInstitute of Molecular Virology, Ulm University Medical Centre, 89081 Ulm, Germany.
Fabian ZechInstitute of Molecular Virology, Ulm University Medical Centre, 89081 Ulm, Germany.
Sabrina NoettgerInstitute of Molecular Virology, Ulm University Medical Centre, 89081 Ulm, Germany.
Christoph JungInstitute of Electrochemistry, Ulm University, 89081 Ulm, Germany; Electrochemical Energy Storage, Helmholtz-Institute-Ulm (HIU), 89081 Ulm, Germany; Karlsruhe Institute of Technology (KIT), 76344 Karlsruhe, Germany.
Timo JacobInstitute of Electrochemistry, Ulm University, 89081 Ulm, Germany.
Theo SandersonFrancis Crick Institute, London MW1 1AT, UK.
Konstantin M J SparrerInstitute of Molecular Virology, Ulm University Medical Centre, 89081 Ulm, Germany.
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Centre, 89081 Ulm, Germany. Electronic address: frank.kirchhoff@uni-ulm.de.
University Hospital Ulm · DEKarlsruhe Institute of Technology · DEThe Francis Crick Institute · GBUniversität Ulm · DE

Funding

Wellcome Trust
6 · The paper itself

Abstract

SARS-CoV-2 Omicron rapidly outcompeted other variants and currently dominates the COVID-19 pandemic. Its enhanced transmission and immune evasion are thought to be driven by numerous mutations in the Omicron Spike protein. Here, we systematically introduced BA.1 and/or BA.2 Omicron Spike mutations into the ancestral Spike protein and examined the impacts on Spike function, processing, and susceptibility to neutralization. Individual mutations of S371F/L, S375F, and T376A in the ACE2-receptor-binding domain as well as Q954H and N969K in the hinge region 1 impaired infectivity, while changes to G339D, D614G, N764K, and L981F moderately enhanced it. Most mutations in the N-terminal region and receptor-binding domain reduced the sensitivity of the Spike protein to neutralization by sera from individuals vaccinated with the BNT162b2 vaccine and by therapeutic antibodies. Our results represent a systematic functional analysis of Omicron Spike adaptations that have allowed this SARS-CoV-2 variant to dominate the current pandemic.

Indexed as

COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineHumansPandemicsSpike Glycoprotein, CoronavirusViral Envelope ProteinsAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Envelope ProteinsBA.1BA.2COVID-19neutralizationOmicronSARS-CoV-2Spike proteinvariant evolution

Identifiers

PMID35931073
PMCPMC9289044
OpenAlexW4285807748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.